Tech Company Financing Transactions

Theraclone Sciences Funding Round

Alexandria Venture Investments, Amgen Ventures and Arch Venture Partners participated in a $14 million Series B funding round for Theraclone Sciences. This venture round was announced on 3/25/2013.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1124 Columbia St. 300
Seattle, WA 98104
USA

Phone

(206) 805-1600

Website

www.theraclone-sciences.com

Email Address

[email protected]

Overview

Theraclone Sciences is a discovery-stage biotech developing novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Clifford Stocks

        

Chief Financial Officer

Russ Hawkinson

        

Chief Scientific Officer

Kristine Swiderek

        

Browse more venture capital transactions:

Prev: 3/25/2013: Achaogen venture capital transaction
Next: 3/25/2013: Minimally Invasive Devices venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary